Responses
Regular and young investigator award abstracts
Checkpoint blockade therapy
215 AO-176, a highly differentiated clinical stage anti-CD47 antibody, preferentially binds tumor versus normal cell CD47 when complexed to β1 integrin
Compose a Response to This Article
Other responses
No responses have been published for this article.